FermaVir Pharmaceuticals, Inc.'s Founder And Board Member Professor Chris McGuigan Receives The Royal Society Of Chemistry's Award For Medicinal Chemistry

NEW YORK--(BUSINESS WIRE)--FermaVir Pharmaceuticals, Inc., (OTCBB:FMVR - News), announced today that the Royal Society of Chemistry will present Professor Chris McGuigan the society’s award for Medicinal Chemistry on the 17th of November at their awards dinner in Glasgow. Professor McGuigan is a founder and Board member of FermaVir. FermaVir has licensed the technology produced in Professor McGuigan’s laboratory for the use in treatment in Shingles and Cytomegalovirus infections. FermaVir’s FV-100, a novel pro-drug antiviral clinical candidate for Shingles, is currently in preclinical studies for filing an Investigational New Drug Application with the FDA.